Recital 17, Regulation (EU) 2020/771

In forcesince 11 Jun 2020

On 13 March 2019, the Authority published a scientific opinion on the safety of Annatto E and the exposure to bixin and norbixin [EFSA Journal 2019;17(3):5626.]. As regards the safety of Annatto E, the Authority concluded that it does not raise concern for genotoxicity and it stated that the ADIs established in 2016 for bixin and norbixin can be applied also to Annatto E. As regards the exposure at the revised uses and use levels submitted by the applicant on 20 July 2018, for bixin, the Authority stated that none of the exposure estimates exceeded the ADI of 6 mg/kg bw per day. For norbixin, the Authority found that the ADI was reached at the high level (95th percentile) for toddlers in the two refined exposure assessment scenarios but only in one country. However, considering the uncertainties and the very likely overestimation of the exposure, the Authority concluded that the level of exposure does not raise a health concern for any of the three scenarios of uses and use levels for bixin and norbixin.